Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
A house in harmony with its surroundings – that was the vision of Kingman Brewster when designing the modern family home…
A house in harmony with its surroundings – that was the vision of Kingman Brewster when designing the modern family home…
LSI/CSI (lsicsi.com), a renowned leader in semiconductor technology, proudly announces the release of its latest innovat…
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program…
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases has ap…
GoldMining Inc. (TSX: GOLD; NYSE AMERICAN: GLDG) ("GoldMining" - https://www.commodity-tv.com/... ) and its subsidiary,…
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target…
HeiQ Blue and Ridge Home Fashions are engaging in a partnership to incorporate multiple innovative textile technologies…
GoldMining Inc. (the "Company" or "GoldMining") (TSX: GOLD; NYSE American: GLDG - https://www.commoditytv. com/ondemand…